Recent studies demonstrate that USP22 is a promising target for cancer immunotherapy, since USP22 positively regulates FOXP3 activity in mouse Treg cells that suppress antitumor immune responses, and Treg-specific USP22-knockout (USP22-Ko) suppressed in vivo Treg function to improve antitumor immunity [31]. This evidence concerns the gene USP22 and cancer.